Total cohort, n=52 | Responders, n=27 | Non-responders, n=22 | P values | |
Demographics | ||||
Age (years, mean±SD) | 72.4±9.4 | 72.0±10.4 | 73.0±8.5 | 0.74 |
Male (n,%) | 43 (82.7%) | 23 (85.2%) | 17 (77.3%) | 0.74 |
Device | ||||
ICD: primary prevention (n, %) | 26 (78.8%) | 16 (88.9%) | 9 (64.3%) | 0.22 |
Upgrade (n, %) | 14 (26.9%) | 5 (18.5%) | 9 (40.9%) | 0.16 |
Aetiology | ||||
Ischaemic (n, %) | 30 (57.7%) | 15 (55.6%) | 13 (59.1%) | 1.00 |
Non-ischaemic (n, %) | 22 (42.3%) | 12 (44.4%) | 9 (40.9%) | |
Comorbidities | ||||
History of atrial fibrillation (n, %) | 28 (53.8%) | 14 (51.9%) | 12 (54.5%) | 1.00 |
Diabetes mellitus (n, %) | 15 (28.8%) | 5 (18.5%) | 9 (40.9%) | 0.16 |
COPD (n, %) | 10 (19.2%) | 3 (11.1%) | 6 (27.3%) | 0.28 |
CKD (n, %) | 23 (44.2%) | 11 (40.7%) | 12 (54.5%) | 0.5 |
NYHA (n, %) II | 20 (38.5%) | 11 (40.7%) | 8 (36.4%) | 0.25 |
III | 27 (51.9%) | 15 (55.6%) | 10 (45.5%) | |
IV | 5 (9.6%) | 1 (3.7%) | 4 (18.2%) | |
Routine blood markers | ||||
eGFR (mL/min/1.73 m2, median, range) | 61.5 (25.0–130.0) | 59 (25.0–130.0) | 58.0 (26.0–99.0) | 0.36 |
Haemoglobin (g/L, mean±SD) | 134.4±13.5 | 136.6±14.1 | 132.5±12.5 | 0.28 |
NT-pro-BNP (pmol/L, median, range) | 248.7 (53.0–4138.0) | 207.0 (53.0–4138.0) | 255.5 (67.0–547.0) | 0.37 |
hs-TnT (ng/L, median, range) | 26.5 (6.5–233.0) | 26.4 (8.5–233.0) | 27.6 (6.5–61.8) | 0.78 |
Medications | ||||
ACEi/ARB (n, %) | 50 (96.2%) | 26 (96.3%) | 21 (95.5%) | 1.00 |
BB (n, %) | 44 (84.6%) | 22 (81.5%) | 21 (95.5%) | 0.24 |
MRA (n, %) | 34 (65.4%) | 17 (63.0%) | 14 (63.6%) | 0.96 |
Aspirin (n, %) | 24 (46.2%) | 13 (48.1%) | 9 (40.9%) | 0.83 |
Clopidogrel (n, %) | 6 (11.5%) | 3 (11.1%) | 3 (13.6%) | 1.00 |
Prasugrel (n, %) | 1 (1.9%) | 1 (3.7%) | 0 (0.0%) | 1.00 |
ECG | ||||
Atrial Fibrillation (n, %) | 19 (36.5%) | 9 (33.3%) | 8 (36.4%) | 0.5 |
QRS duration (ms, median, range) | 164.0 (120–240) | 168.0 (146–240) | 159.0 (120–210) | 0.11 |
LBBB (n,%) | 39 (75.0%) | 23 (85.2%) | 14 (63.6%) | 0.16 |
QoL Score (median, range) | 48.5 (8–101) | 50 (9–86) | 48.5 (8–101) | 0.77 |
6MWT (M, mean±SD) | 238.8±130.6 | 237.6±130.5 | 239.4±127.4 | 0.95 |
Echocardiogram | ||||
LVEDD (mm, mean±SD)* | 61.7±10.1 | 62.9±11.2 | 60.2±9.0 | 0.4 |
LVESV (mL, median, range)* | 111.5 (49–219) | 119.3 (49–269) | 110.2 (56–169) | 0.41 |
LVESV_BSA (mL, mean±SD)* | 61.3±21.5 | 65.7±25.8 | 56.6±16.3 | 0.26 |
LVEF (%, mean±SD)* | 24.3±8.0 | 24.1±7.9 | 24.4±8.7 | 0.91 |
LV lead circumferential position (n, %) | ||||
Anterior | 5 (9.6%) | 2 (7.4%) | 3 (13.6%) | 0.64 |
Anterolateral | 3 (5.8%) | 2 (7.4%) | 1 (4.5%) | |
Lateral | 28 (53.8%) | 13 (37.0%) | 13 (59.1%) | |
Posterolateral | 16 (30.8%) | 10 (37.0%) | 5 (22.7%) | |
LV lead axial position Basal (n, %) | 29 (55.8%) | 15 (55.6%) | 11 (50.0%) | 0.7 |
Mid-Cavity (n, %) | 23 (44.2%) | 12 (44.4%) | 11 (50.0%) |
~ = proportion of patients with defibrillators only,
*Represents data available.
ACEi, angiotension converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; BSA, body surface area; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LBBB, left bundle branch block; LVEDV, LV end diastolic volume; LVEF, left ventricular ejection fraction; LVESD, LV end systolic diameter; LVESV, left ventricular end systolic volume; LVIDD, LV end diastolic diameter; MI, myocardial Infarction; MRA, mineral corticoid receptor antagonist; PCI, percutaneous coronary intervention; QoL, Qualiy of Life.